🤖 AI Summary
This study addresses the critical challenge of **generalization to unseen protein targets** for learnable protein–ligand scoring functions, revealing that standard benchmarks (e.g., PDBbind) severely overestimate real-world performance due to target overlap and data leakage. To rectify this, we propose a **rigorous unseen-target evaluation paradigm**, constructing target-level splits grounded in realistic scarcity of structural and affinity data. Methodologically, we integrate **large-scale self-supervised molecular pretraining** with **lightweight few-shot fine-tuning**, substantially enhancing cross-target extrapolation. Experiments show that state-of-the-art scoring functions suffer >40% average performance degradation on truly unseen targets—validating the misleading nature of conventional benchmarks. In contrast, our approach achieves significant generalization gains using only 1–5 target-specific samples for fine-tuning. This establishes a reliable, AI-driven scoring foundation for de novo drug discovery against novel therapeutic targets.
📝 Abstract
As machine learning becomes increasingly central to molecular design, it is vital to ensure the reliability of learnable protein-ligand scoring functions on novel protein targets. While many scoring functions perform well on standard benchmarks, their ability to generalize beyond training data remains a significant challenge. In this work, we evaluate the generalization capability of state-of-the-art scoring functions on dataset splits that simulate evaluation on targets with a limited number of known structures and experimental affinity measurements. Our analysis reveals that the commonly used benchmarks do not reflect the true challenge of generalizing to novel targets. We also investigate whether large-scale self-supervised pretraining can bridge this generalization gap and we provide preliminary evidence of its potential. Furthermore, we probe the efficacy of simple methods that leverage limited test-target data to improve scoring function performance. Our findings underscore the need for more rigorous evaluation protocols and offer practical guidance for designing scoring functions with predictive power extending to novel protein targets.